Meeting on the Mesa 2021 | NKX019 in B-cell malignancies

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, describes the development of NKX019, an off-the-shelf CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy in patients with B-cell malignancies including lymphomas and leukemias. NKX019 aims to address current challenges CAR-T cell therapies face by improving safety and patient accessibility whilst maintaining efficacy. This interview took place at Meeting on the Mesa 2021.